Intralesional bleomycin for treatment of a recalcitrant wart in an immunocompromised patient: A safe, effective, and underutilized therapy

Injectable bleomycin is infrequently used for recalcitrant warts despite its efficacy, acceptable safety profile, and high patient satisfaction compared with other treatment modalities. We present an immunocompromised patient with a large recalcitrant wart successfully treated with intralesional ble...

Descripción completa

Detalles Bibliográficos
Autores principales: Ngo, Tracy, Hwang, Hannah, Amin, Bijal, Cohen, Steven R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924998/
https://www.ncbi.nlm.nih.gov/pubmed/35317064
http://dx.doi.org/10.1002/ccr3.5613
_version_ 1784669974573350912
author Ngo, Tracy
Hwang, Hannah
Amin, Bijal
Cohen, Steven R.
author_facet Ngo, Tracy
Hwang, Hannah
Amin, Bijal
Cohen, Steven R.
author_sort Ngo, Tracy
collection PubMed
description Injectable bleomycin is infrequently used for recalcitrant warts despite its efficacy, acceptable safety profile, and high patient satisfaction compared with other treatment modalities. We present an immunocompromised patient with a large recalcitrant wart successfully treated with intralesional bleomycin to provide greater clinical exposure, training, and practice with intralesional bleomycin.
format Online
Article
Text
id pubmed-8924998
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89249982022-03-21 Intralesional bleomycin for treatment of a recalcitrant wart in an immunocompromised patient: A safe, effective, and underutilized therapy Ngo, Tracy Hwang, Hannah Amin, Bijal Cohen, Steven R. Clin Case Rep Case Reports Injectable bleomycin is infrequently used for recalcitrant warts despite its efficacy, acceptable safety profile, and high patient satisfaction compared with other treatment modalities. We present an immunocompromised patient with a large recalcitrant wart successfully treated with intralesional bleomycin to provide greater clinical exposure, training, and practice with intralesional bleomycin. John Wiley and Sons Inc. 2022-03-16 /pmc/articles/PMC8924998/ /pubmed/35317064 http://dx.doi.org/10.1002/ccr3.5613 Text en © 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Ngo, Tracy
Hwang, Hannah
Amin, Bijal
Cohen, Steven R.
Intralesional bleomycin for treatment of a recalcitrant wart in an immunocompromised patient: A safe, effective, and underutilized therapy
title Intralesional bleomycin for treatment of a recalcitrant wart in an immunocompromised patient: A safe, effective, and underutilized therapy
title_full Intralesional bleomycin for treatment of a recalcitrant wart in an immunocompromised patient: A safe, effective, and underutilized therapy
title_fullStr Intralesional bleomycin for treatment of a recalcitrant wart in an immunocompromised patient: A safe, effective, and underutilized therapy
title_full_unstemmed Intralesional bleomycin for treatment of a recalcitrant wart in an immunocompromised patient: A safe, effective, and underutilized therapy
title_short Intralesional bleomycin for treatment of a recalcitrant wart in an immunocompromised patient: A safe, effective, and underutilized therapy
title_sort intralesional bleomycin for treatment of a recalcitrant wart in an immunocompromised patient: a safe, effective, and underutilized therapy
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924998/
https://www.ncbi.nlm.nih.gov/pubmed/35317064
http://dx.doi.org/10.1002/ccr3.5613
work_keys_str_mv AT ngotracy intralesionalbleomycinfortreatmentofarecalcitrantwartinanimmunocompromisedpatientasafeeffectiveandunderutilizedtherapy
AT hwanghannah intralesionalbleomycinfortreatmentofarecalcitrantwartinanimmunocompromisedpatientasafeeffectiveandunderutilizedtherapy
AT aminbijal intralesionalbleomycinfortreatmentofarecalcitrantwartinanimmunocompromisedpatientasafeeffectiveandunderutilizedtherapy
AT cohenstevenr intralesionalbleomycinfortreatmentofarecalcitrantwartinanimmunocompromisedpatientasafeeffectiveandunderutilizedtherapy

Ejemplares similares